Global Biosimilar Monoclonal Antibodies Market: Trend Analysis and Forecast to 2022


Select Your License Type


samplerequest
makeanenquiry
download
Discount




                                     Figure : Global Biosimilar Monoclonal Antibodies Market By Region


The Biosimilar Monoclonal Antibodies Market is driven by rituximab and infliximab submarkets, the rituximab submarket is accounted as the highest holding market share submarket and the infliximab submarket will become the leading submarket by 2018 continuing its dominance until 2022. A monoclonal antibody is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. A monoclonal antibody is made so that it binds to only one substance to treat different types of cancer. There are several types of monoclonal antibodies that are being used to treat certain types of cancer. Laboratory production of monoclonal antibodies is produced from clones of only one cell which means that every monoclonal antibody produced by the cell is the same due to which they are called as biosimilar monoclonal antibodies. Each monoclonal antibody recognizes one particular protein. They work in different ways depending on the protein they are targeting, hence different monoclonal antibodies are required to be made to target different types of cancers.

In 2014, the size of the global biosimilar monoclonal antibodies market was valued over USD 352 million. While in 2015, the market size reached to USD xxx.x million. The global biosimilar monoclonal antibodies market is projected to grow with a CAGR between 42.9% and 43.5% during 2016-2022 and reach USD xxxx.x million by 2022. Patient expiration of biologics, innovative product in the pipeline and increasing healthcare infrastructure are expected to be key factors driving the growth of global biosimilar monoclonal antibodies market. However, unfavorable government regulations and development policies, undesirable manufacturing process and cost structure associated with the manufacturing process are considered to be restraining factors in the global biosimilar monoclonal antibodies market. Furthermore, increasing demand for cost effective treatment, collaboration with the local players and high profitability in the market are the key opportunities for the companies to invest in the biosimilar monoclonal antibodies market.

Segments Covered:

The report segments the global biosimilar monoclonal antibodies market by drug class and by application.The market segmentation based on drug class includes, rituximab, infliximab, abciximab, trastuzumab, adalimumab, and bevacizumab. Moreover, based on application the biosimilar monoclonal antibodies market is segmented into oncology, chronic and auto immune diseases, growth hormone deficiency and infectious diseases.

Geographic Coverage and Analysis:

The report provides regional analysis covering geographies such as North America, Europe, Asia Pacific, Latin America, and Rest of the World (RoW). Europe is the largest biosimilar monoclonal antibodies market globally. Due to favorable regulatory policies designed by the European Medical Association (EMA) and since Europe was the first region to draft guidelines for approval of biosimilar products, the European market has a largest these market share on the market. Asia pacific is expected to grow at the highest CAGR over the forecast period and provides the opportunity to market growth due to increasing demand of cost effective treatment to the prevalence of chronic diseases and launch of new biosimilar monoclonal antibodies. Nevertheless, government investment in healthcare will also act as a growth opportunity for biosimilar monoclonal antibodies market  in the Asia-Pacific region.

Companies Profiled:

The companies covered in the report include

  • Pfizer Inc
  • Novartis AG
  • Reliance Life Sciences
  • Allergan plc
  • Coherus BioSciences Inc
  • Biocon
  • Dr. Reddy’s Laboratories Ltd.
  • Boehringer Ingelheim GmbH
  • BioXpress Therapeutics SA
  • Intas Pharmaceuticals Limited
  • BIOCAD
  • Genor BioPharma Co. Ltd
  • Celltrion Inc

Report Highlights:

The report on Biosimilar Monoclonal Antibodies Market provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of biosimilars monoclonal antibodies globally as well as regionally. Moreover, IGR-Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider.  The report provides insights into the market using analytical tools such as Porter’s five forces analysis and value chain analysis of biosimilar monoclonal antibodies market. Moreover, the study highlights current market trends and provides forecast from 2016 to 2022. We also have highlighted future trends in the biosimilar monoclonal antibodies market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. Additionally, the analysis highlights rise and fall in the market shares of the key players in the market.

The report also provides in depth analysis of regulatory framework pertaining to Biosimilar Monoclonal Antibodies Market. This will help the companies to understand the regulatory compliances, supports, barriers in the Biosimilar Monoclonal Antibodies market. This section highlights key amendments and their implication on Biosimilar Monoclonal Antibodie market in the short run as well as in the long run.This report will help manufacturers, suppliers and distributors of the biosimilar monoclonal antibodies market to understand the present and future trends in this market and formulate their strategies accordingly.

1. Report Overview

1.1 Report Description
1.2 Research Methods
1.3 Research Approaches

2. Executive Summary

3.Global Biosimilar Monoclonal Antibodies Market Overview

3.1 Introduction
3.2 Market Dynamics
3.3 Drivers
3.4 Restraints
3.5 Opportunities
3.6 Challenges
3.7 Porter’s Five Forces Analysis
3.8 IGR – Growth Matrix Analysis
3.9 Competitive Landscape in the Biosimilar Monoclonal Antibodies Market
3.10 : Regulatory Framework analysis by region

3.10.1: North America
3.10.2 Europe
3.10.3 RoW (Including APAC, and LATAM)

4. Global Biosimilar Monoclonal Antibodies Market, by Drug Class, (USD Million) 2015 – 2022

4.1 Introduction
4.2 Rituximab
4.3 Infliximab
4.4 Abciximab
4.5 Trastuzumab
4.6 Adalimumab
4.7 Bevacizumab

5. Global Biosimilar Monoclonal Antibodies Market, by Application, (USD Million) 2015 – 2022

5.1 Introduction
5.2 Oncology
5.3 Chronic and Autoimmune Diseases
5.4 Growth Hormone Deficiency
5.5 Infectious Diseases
5.6 Others

6. Global Biosimilar Monoclonal Antibodies Market, by Region, (USD Million) 2015 – 2022

6.1 Introduction

6.2 North America

6.2.1 North America Biosimilar Monoclonal Antibodies Market, byDrug Class (USD Million)
6.2.2 North America Biosimilar Monoclonal Antibodies Market, by Application (USD Million)

6.3 Europe

6.3.1 Europe Biosimilar Monoclonal Antibodies Market, byDrug Class (USD Million)
6.3.2 Europe Biosimilar Monoclonal Antibodies Market, by Application (USD Million)

6.4 Asia Pacific

6.4.1 Asia Pacific Biosimilar Monoclonal Antibodies Market, byDrug Class (USD Million)
6.4.2 Asia Pacific Biosimilar Monoclonal Antibodies Market, by Application (USD Million)

6.5 Latin America

6.5.1 Latin America Biosimilar Monoclonal Antibodies Market, byDrug Class (USD Million)
6.5.2 Latin America Biosimilar Monoclonal Antibodies Market, by Application (USD Million)

6.6 Rest of the World

6.6.1 RoWBiosimilar Monoclonal Antibodies Market, byDrug Class (USD Million)
6.6.2 RoWBiosimilar Monoclonal Antibodies Market, by Application (USD Million)7. Leading Companies

7.1 Company Profiles

7.1.1 Pfizer, Inc.
7.1.2 Novartis AG
7.1.3 Reliance Life Sciences
7.1.4 Allergan plc
7.1.5 CoherusBioSciences, Inc.
7.1.6 Biocon
7.1.7 Dr. Reddy’s Laboratories Ltd.
7.1.8 BoehringerIngelheim GmbH
7.1.9 BioXpress Therapeutics SA
7.1.10 Intas Pharmaceuticals Limited
7.1.11 BIOCAD
7.1.12 GenorBioPharma Co. Ltd
7.1.13 Celltrion, Inc.


Got a Question?

If you have a question to ask our analyst, just fill this form and send it across, our representative will get in touch with you shortly.